Synergistic Peptide Combinations Designed to Suppress SARS-CoV-2

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 May 10

PMID 38726116

Authors

Tao Han

Linhong Song

Xinxin Niu

Meng Qiu

Yi Wang

Jing Wang

Xiuyan Sun

Jiali Ma

Siqi Hu

Zhichun Feng

Affiliations

Soon will be listed here.

Abstract

The SARS-CoV-2, responsible for the COVID-19 pandemic, poses a significant threat to global healthcare. Peptide and peptide-based inhibitors, known for their safety, efficacy, and selectivity, have recently emerged as promising candidates for treating late-developing viral infections. In this study, three peptides were selected to target different stages of viral invasion, specifically ACE2 and S protein binding, as well as membrane fusion. The objective was to assess their ability to impede the entry of the SARS-CoV-2 Spike pseudotyped virus. Our findings revealed that a combination of these three peptides demonstrated enhanced antiviral effects. This outcome substantiates the feasibility of developing effective peptide combinations to combat diseases related to SARS-CoV-2. Moreover, the three-peptide combinations, designed to target multiple aspects of SARS-CoV-2 viral entry, exhibited heightened viral inhibition and broad-spectrum antiviral properties.

Citing Articles

Immunogenic Potential of Selected Peptides from SARS-CoV-2 Proteins and Their Ability to Block S1/ACE-2 Binding.

da Silva Lima L, Woiski T, de Moura J, Rosati R, Minozzo J, da Silva E Viruses. 2025; 17(2).

PMID: 40006920 PMC: 11860825. DOI: 10.3390/v17020165.

References

Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S . Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020; 30(4):343-355. PMC: 7104723. DOI: 10.1038/s41422-020-0305-x. View

Wu L, Zheng A, Tang Y, Chai Y, Chen J, Cheng L . A pan-coronavirus peptide inhibitor prevents SARS-CoV-2 infection in mice by intranasal delivery. Sci China Life Sci. 2023; 66(10):2201-2213. DOI: 10.1007/s11427-023-2410-5. View

Vellingiri B, Jayaramayya K, Iyer M, Narayanasamy A, Govindasamy V, Giridharan B . COVID-19: A promising cure for the global panic. Sci Total Environ. 2020; 725:138277. PMC: 7128376. DOI: 10.1016/j.scitotenv.2020.138277. View

Kaufmann S, Dorhoi A, Hotchkiss R, Bartenschlager R . Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov. 2017; 17(1):35-56. PMC: 7097079. DOI: 10.1038/nrd.2017.162. View

Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G . Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther. 2022; 7(1):48. PMC: 8844085. DOI: 10.1038/s41392-022-00904-4. View

Kang H, Kim C, Seo C, Park Y . The therapeutic applications of antimicrobial peptides (AMPs): a patent review. J Microbiol. 2016; 55(1):1-12. DOI: 10.1007/s12275-017-6452-1. View

Markov P, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis N . The evolution of SARS-CoV-2. Nat Rev Microbiol. 2023; 21(6):361-379. DOI: 10.1038/s41579-023-00878-2. View

Xia S, Chan J, Wang L, Jiao F, Chik K, Chu H . Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. Cell Res. 2022; 32(4):404-406. PMC: 8793821. DOI: 10.1038/s41422-022-00617-x. View

Chou T . Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006; 58(3):621-81. DOI: 10.1124/pr.58.3.10. View

10.

Ou X, Liu Y, Lei X, Li P, Mi D, Ren L . Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020; 11(1):1620. PMC: 7100515. DOI: 10.1038/s41467-020-15562-9. View

11.

Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B . A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005; 11(8):875-9. PMC: 7095783. DOI: 10.1038/nm1267. View

12.

Zhu Z, Lian X, Su X, Wu W, Marraro G, Zeng Y . From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir Res. 2020; 21(1):224. PMC: 7450684. DOI: 10.1186/s12931-020-01479-w. View

13.

Xia S, Zhu Y, Liu M, Lan Q, Xu W, Wu Y . Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020; 17(7):765-767. PMC: 7075278. DOI: 10.1038/s41423-020-0374-2. View

14.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

15.

Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

16.

Li P, Hu J, Liu Y, Ou X, Mu Z, Lu X . Effect of polymorphism in Rhinolophus affinis ACE2 on entry of SARS-CoV-2 related bat coronaviruses. PLoS Pathog. 2023; 19(1):e1011116. PMC: 9904459. DOI: 10.1371/journal.ppat.1011116. View

17.

Zhu Y, Yu D, Yan H, Chong H, He Y . Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. J Virol. 2020; 94(14). PMC: 7343218. DOI: 10.1128/JVI.00635-20. View

18.

Lu Y, Tian H, Chen R, Liu Q, Jia K, Hu D . Synergistic Antimicrobial Effect of Antimicrobial Peptides CATH-1, CATH-3, and PMAP-36 With Erythromycin Against Bacterial Pathogens. Front Microbiol. 2022; 13:953720. PMC: 9335283. DOI: 10.3389/fmicb.2022.953720. View

19.

Han D, Penn-Nicholson A, Cho M . Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. Virology. 2006; 350(1):15-25. PMC: 7111894. DOI: 10.1016/j.virol.2006.01.029. View

20.

Kang X, Dong F, Shi C, Liu S, Sun J, Chen J . DRAMP 2.0, an updated data repository of antimicrobial peptides. Sci Data. 2019; 6(1):148. PMC: 6692298. DOI: 10.1038/s41597-019-0154-y. View